Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979. It is grouped under the following drug class(es): Antianginals and Beta blockers. Its therapeutic use is listed as angina, antiarrhythmics, antihypertensives, cardiovascular and migraine preventive agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Solgol, Corgard, (2R, 3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1, 2, 3, 4-tetrahydronaphthalene-2 and 3-diol. Its PubChem CID is 39147.
Nadolol
| CAS No | 220045-89-6 |
|---|---|
| Molecular Formula | C17H27NO4 |
| Molecular Weight | 309.4 g/mol |
| Synonyms | (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
The listed CAS number is 220045-89-6.
The listed molecular formula is C17H27NO4.
The listed molecular weight is 309.4 g/mol.
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.
The source lists Solgol, Corgard, (2R, 3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1, 2, 3, 4-tetrahydronaphthalene-2 and 3-diol.